The Centers for Medicare and Medicaid Services does not need to add an evaluation of the impact manufacturer rebates have on Medicare Part D formulary design and beneficiary costs to its annual formulary review process at this point, the Department of Health and Human Services told the General Accountability Office in response to a recent GAO report.
GAO Report Highlights
-
Part D plans received $48.6bn in manufacturer rebates in 2021.
CMS conducts an annual clinical formulary review in Part D that includes evaluating whether formularies include commonly prescribed drug classes....







